AR028619A1 - Un compuesto inhibidor de caspasas - Google Patents
Un compuesto inhibidor de caspasasInfo
- Publication number
- AR028619A1 AR028619A1 ARP010102477A ARP010102477A AR028619A1 AR 028619 A1 AR028619 A1 AR 028619A1 AR P010102477 A ARP010102477 A AR P010102477A AR P010102477 A ARP010102477 A AR P010102477A AR 028619 A1 AR028619 A1 AR 028619A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- ring
- aryl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Abstract
Inhibidores de caspasas que tienen la formula (1) en donde el anillo A es un anillo opcionalmente sustituido con piperidina tetrahidroquinolina o tetrahidroisoquinolina; R1 es hidrogeno, CHN2, R, o CH2Y; R es un grupo opcionalmente sustituido seleccionado ente un grupo alifático, un grupo arilo, un grupo aralquilo, un grupo heterociclilo, o un grupo heterociclilalquilo; Y es un grupo saliente electronegativo; R2 es CO2H, CH2CO2H o ésteres, amidas o isosteros del mismo; Ar es un grupo arilo opcionalmente sustituido; y R3 es hidrogeno, un alquilo C1-6 opcionalmente sustituido, F2, CN, arilo o R3 es ligado a Ar para formar un anillo fusionado de cinco o seis miembros no saturado o parcialmente saturado que tiene 0-2 heteroátomos. Los compuestos son utiles para tratar en mamíferos enfermedades en las cuales las caspasas hacen de intermediaria. También es objeto de la presente solicitud una composicion farmacéutica y método de tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20636200P | 2000-05-23 | 2000-05-23 | |
US21700600P | 2000-07-10 | 2000-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR028619A1 true AR028619A1 (es) | 2003-05-14 |
Family
ID=26901274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010102477A AR028619A1 (es) | 2000-05-23 | 2001-05-23 | Un compuesto inhibidor de caspasas |
Country Status (16)
Country | Link |
---|---|
US (1) | US7053057B2 (es) |
EP (1) | EP1283827A2 (es) |
JP (1) | JP2003534325A (es) |
KR (1) | KR20020025959A (es) |
AP (1) | AP2002002407A0 (es) |
AR (1) | AR028619A1 (es) |
AU (1) | AU2001265008A1 (es) |
CA (1) | CA2380935A1 (es) |
MX (1) | MXPA02000823A (es) |
NO (1) | NO20020343L (es) |
NZ (1) | NZ516918A (es) |
PE (1) | PE20020058A1 (es) |
PL (1) | PL357713A1 (es) |
SK (1) | SK1192002A3 (es) |
TR (1) | TR200200767T1 (es) |
WO (1) | WO2001090070A2 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1176941C (zh) | 1999-04-09 | 2004-11-24 | 西托维亚公司 | Caspase抑制剂及其应用 |
AU6894800A (en) | 1999-08-06 | 2001-03-05 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
CN1235875C (zh) | 1999-08-27 | 2006-01-11 | 西托维亚公司 | 取代的α-羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AU2003211052A1 (en) | 2002-02-11 | 2003-09-04 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
EP1499898A2 (en) | 2002-04-19 | 2005-01-26 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
US20060212020A1 (en) * | 2002-10-10 | 2006-09-21 | Lynne Rainen | Sample collection system with caspase inhibitor |
EP1626732B1 (en) * | 2003-05-22 | 2013-04-03 | CHIESI FARMACEUTICI S.p.A. | Means for preventing and treating cellular death and their biological applications |
AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
RU2382780C2 (ru) * | 2004-02-27 | 2010-02-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы каспаз и их применение |
DK2399916T3 (en) * | 2004-03-12 | 2015-03-02 | Vertex Pharma | A process and intermediates for the preparation of asparaginacetal-caspase inhibitors |
ME02125B (me) * | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
EP1740614A2 (en) * | 2004-04-30 | 2007-01-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
CN102362867A (zh) * | 2004-05-15 | 2012-02-29 | 沃泰克斯药物股份有限公司 | 使用ice抑制剂治疗癫痫发作 |
EP1778221A2 (en) | 2004-05-27 | 2007-05-02 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
ES2312012T3 (es) | 2004-09-17 | 2009-02-16 | Biomas Ltd. | Nuevos compuestos de telurio y su uso como inmunomodulares. |
JP2009502922A (ja) * | 2005-07-28 | 2009-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼ阻害剤プロドラッグ |
PE20080951A1 (es) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
EP2054076A2 (en) * | 2006-08-21 | 2009-05-06 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
EP2102229B1 (en) | 2006-10-12 | 2014-03-26 | Novartis AG | Pyrrolydine derivatives as iap inhibitors |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
WO2008137567A1 (en) * | 2007-05-01 | 2008-11-13 | Cedars-Sinai Medical Center | Caspase inhibitors in the treatment of infection-associated preterm delivery |
JP2011524340A (ja) | 2008-05-21 | 2011-09-01 | ニュー・ワールド・ラボラトリーズ・インコーポレイテッド | 選択的カスパーゼ阻害剤およびその使用 |
US9045524B2 (en) | 2009-05-21 | 2015-06-02 | Novagenesis Foundation | Selective caspase inhibitors and uses thereof |
WO2012061786A1 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
ES2665301T3 (es) | 2011-04-15 | 2018-04-25 | Genesis Technologies Limited | Inhibidores selectivos de cisteína proreasa y usos de los mismos |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
AU2015259471A1 (en) | 2014-05-12 | 2016-11-24 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitors |
EP3247378B8 (en) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
CA3000822A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
WO2017180748A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
CN105853408B (zh) * | 2016-04-15 | 2018-12-04 | 浙江大学 | 苯酰胺衍生物在制备Caspase-1抑制剂中的应用 |
EP3456711A4 (en) * | 2016-05-11 | 2019-10-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR |
US20190231770A1 (en) | 2016-10-05 | 2019-08-01 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic, cirrhotic disease or disorder |
US11479797B2 (en) | 2016-10-28 | 2022-10-25 | Ginkgo Bioworks, Inc. | Compositions and methods for the production of compounds |
CN110177774B (zh) * | 2017-01-23 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
CN109748843B (zh) * | 2017-11-06 | 2022-11-11 | 正大天晴药业集团股份有限公司 | Caspase抑制剂及其药物组合物、用途和治疗方法 |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015577A1 (en) * | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
WO1995005192A1 (en) * | 1993-08-13 | 1995-02-23 | Merck & Co., Inc. | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
EP0900791A1 (en) * | 1995-12-27 | 1999-03-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
BR9814817A (pt) * | 1997-10-10 | 2002-01-08 | Cytovia Inc | Inibidores de apoptose de dipeptìdio e o uso dos mesmos |
EP1076563B1 (en) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
-
2001
- 2001-05-23 PE PE2001000468A patent/PE20020058A1/es not_active Application Discontinuation
- 2001-05-23 NZ NZ516918A patent/NZ516918A/en unknown
- 2001-05-23 EP EP01939497A patent/EP1283827A2/en not_active Withdrawn
- 2001-05-23 WO PCT/US2001/017075 patent/WO2001090070A2/en active IP Right Grant
- 2001-05-23 KR KR1020027000995A patent/KR20020025959A/ko not_active Application Discontinuation
- 2001-05-23 CA CA002380935A patent/CA2380935A1/en not_active Abandoned
- 2001-05-23 TR TR2002/00767T patent/TR200200767T1/xx unknown
- 2001-05-23 AR ARP010102477A patent/AR028619A1/es unknown
- 2001-05-23 MX MXPA02000823A patent/MXPA02000823A/es not_active Application Discontinuation
- 2001-05-23 JP JP2001586259A patent/JP2003534325A/ja active Pending
- 2001-05-23 US US09/863,649 patent/US7053057B2/en not_active Expired - Fee Related
- 2001-05-23 SK SK119-2002A patent/SK1192002A3/sk unknown
- 2001-05-23 AU AU2001265008A patent/AU2001265008A1/en not_active Abandoned
- 2001-05-23 PL PL01357713A patent/PL357713A1/xx not_active Application Discontinuation
- 2001-05-23 AP APAP/P/2002/002407A patent/AP2002002407A0/en unknown
-
2002
- 2002-01-22 NO NO20020343A patent/NO20020343L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20020061853A1 (en) | 2002-05-23 |
CA2380935A1 (en) | 2001-11-29 |
MXPA02000823A (es) | 2002-07-30 |
US7053057B2 (en) | 2006-05-30 |
PL357713A1 (en) | 2004-07-26 |
EP1283827A2 (en) | 2003-02-19 |
NZ516918A (en) | 2004-06-25 |
NO20020343D0 (no) | 2002-01-22 |
JP2003534325A (ja) | 2003-11-18 |
NO20020343L (no) | 2002-03-21 |
SK1192002A3 (en) | 2002-09-10 |
PE20020058A1 (es) | 2002-01-31 |
AP2002002407A0 (en) | 2002-03-31 |
WO2001090070A3 (en) | 2002-04-11 |
KR20020025959A (ko) | 2002-04-04 |
AU2001265008A1 (en) | 2001-12-03 |
TR200200767T1 (tr) | 2002-09-23 |
WO2001090070A2 (en) | 2001-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR028619A1 (es) | Un compuesto inhibidor de caspasas | |
AR031809A1 (es) | Quinolonas antimicrobianas, sus composiciones y usos | |
EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
LU92146I2 (fr) | Dasatinib et ses sels pharmaceutiquement acceptables | |
PE20050729A1 (es) | Aminas ciclicas sustituidas por bezamida o piridin-carboxamida como inhibidores de bace-1 | |
BR9506452A (pt) | Composto heterocíclico processo de preparação do composto heterocíclico composição farmacêutica composição farmacêutica adequada para o tratamento de inflamação neurogênica processo de tratamento de inflamação neurogênica em um individuo necessitado de tal tratamento e uso de um composto heterocíclico | |
IL152845A0 (en) | Fused heterocyclic compounds and pharmaceutical compositions containing the same | |
EA200400944A1 (ru) | Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием | |
ATE510837T1 (de) | Caspase inhibitoren und deren verwendung | |
ATE189218T1 (de) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
CO5570667A2 (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades | |
EA200501098A1 (ru) | Антибактериальные агенты | |
BR0109467A (pt) | Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto | |
EA200600732A1 (ru) | Макроциклические карбоновые кислоты и ацилсульфонамиды в качестве ингибиторов репликации вируса гепатита с | |
PE59099A1 (es) | Nuevos derivados del acido hexanoico | |
EA200800413A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
FI971202A0 (fi) | Levobupivakaiinin ja sen analogien valmistuksessa käytettäviä menetelmiä rasemisoinnin ja asymmetrisen muuntamisen tekemiseksi | |
AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
AR022220A1 (es) | Derivados de la imidazo[4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones fa | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
DE69615169D1 (de) | N-substituierte azaheterocyclische Carbonsäuren und ihre Alkylester | |
AR020768A1 (es) | Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso | |
EA200501083A1 (ru) | Соединения, активные в ингибировании пролилолигопептидазы | |
ATE293602T1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 | |
ATE205843T1 (de) | Heterocyclische verbindungen zur behandlung von neurogener entzündung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |